1-6 of 6
Ruben Niesvizky
Close
Sort by
Journal Articles

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, Tarek H. Mouhieddine, Juan Esteban Velez-Hernandez, Katherine Engles, Joshua A. Fein, Jorge Monge, Cara Rosenbaum, Roger Pearse, David Jayabalan, Christian Gordillo, Hei Ton Chan, Samuel Yamshon, Santiago Thibaud, Markus Mapara, Giorgio Inghirami, Suzanne Lentzsch, Ran Reshef, Adriana Rossi, Samir Parekh, Sundar Jagannath, Shambavi Richard, Ruben Niesvizky, Mark Bustoros
Journal: Blood Advances
Blood Adv (2024) 8 (15): 3859–3869.
https://doi.org/10.1182/bloodadvances.2023012470
Published: 2024
Includes: Supplemental data
Journal Articles

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies

Olivia Perez de Acha, Lauren Reiman, David S. Jayabalan, Zachary J. Walker, Grace Bosma, Alana L. Keller, Sarah E. Parzych, Diana Abbott, Beau M. Idler, Drew Ribadeneyra, Ruben Niesvizky, Peter A. Forsberg, Tomer M. Mark, Daniel W. Sherbenou
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6430–6440.
https://doi.org/10.1182/bloodadvances.2023010162
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis

Clinical Trials & Observations
Cara A. Rosenbaum, Umut Özbek, Larysa Sanchez, Jonathan Lagdameo, Alex Abrahams, Hani Hassoun, Oscar Lahoud, Ruben Niesvizky, Heather J. Landau, Keren Osman
Journal: Blood Advances
Blood Adv (2022) 6 (18): 5436–5439.
https://doi.org/10.1182/bloodadvances.2022007826
Published: 2022
Journal Articles

Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma

Clinical Trials & Observations
Shaji Kumar, Alan Fu, Ruben Niesvizky, Sundar Jagannath, Ralph Boccia, Noopur Raje
Journal: Blood Advances
Blood Adv (2021) 5 (2): 367–376.
https://doi.org/10.1182/bloodadvances.2019001059
Published: 2021
Includes: Supplemental data
Journal Articles

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

Clinical Trials & Observations
Thierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, David Siegel, Cara Rosenbaum, Sara Bringhen, Katja Weisel, P. Joy Ho, Heinz Ludwig, Shaji Kumar, Kenneth Wang, Mihaela Obreja, Zhao Yang, Zandra Klippel, Khalid Mezzi, Amanda Goldrick, Christina Tekle, Meletios A. Dimopoulos
Journal: Blood Advances
Blood Adv (2020) 4 (21): 5449–5459.
https://doi.org/10.1182/bloodadvances.2020001965
Published: 2020
Includes: Supplemental data
Journal Articles

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma

Clinical Trials & Observations
Tomer M. Mark, Peter A. Forsberg, Adriana C. Rossi, Roger N. Pearse, Karen A. Pekle, Arthur Perry, Angelique Boyer, Linda Tegnestam, David Jayabalan, Morton Coleman, Ruben Niesvizky
Journal: Blood Advances
Blood Adv (2019) 3 (4): 603–611.
https://doi.org/10.1182/bloodadvances.2018028027
Published: 2019
Includes: Supplemental data